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Abstract 13 
The aim of this work was to assess the viability of some commercial probiotics after 14 
exposure to gastric acid and the possibility of modifying these formulations for 15 
delivery into the distal parts of the intestines. Gastrointestinal tolerance testing was 16 
conducted for three commercial probiotics and an in-house freeze-dried 17 
Lactobacillus acidophilus strain. The contents of the commercial products and the in-18 
house freeze-dried strain were then loaded into capsules for site-specific delivery 19 
into the colon using the Phloral® coating technology; the viability upon release was 20 
then ascertained. An assessment of the potential of these products to adhere to 21 
intestinal cells was also conducted. The results showed that all the commercial 22 
products contained the minimum number of probiotic strains as indicated on their 23 
respective packages. When gastric acid tolerance tests were performed on these 24 
products, all the commercial probiotics and the prepared freeze-dried strain 25 
demonstrated over 106 CFU reductions within 5 minutes. When these were 26 
encapsulated for site-specific delivery into the distal parts of the gut, viabilities of 27 
approximately 90% were obtained after these capsules had been initially deposited 28 
in gastric acid for 2 hours. An evaluation of the ability of the probiotic formulations to 29 
adhere to intestinal cells demonstrated adhesion in the range 64-76% for the 30 
products evaluated. The need to target the delivery of probiotics into the intestines 31 
has been demonstrated here as this offers a greater potential for colonisation of the 32 
intestines once the harshness of the stomach has been overcome.  33 
 34 
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1 Introduction 37 
In recent years, there has been an increased interest in the use of probiotics with 38 
several probiotic products on the market with various delivery mechanisms. The 39 
concept of probiotics emerged from the early 20th century when the Russian 40 
immunologist Elie Metchnikoff observed that Bulgarian peasant farmers had long life-41 
spans. He suggested this was due to the consumption of large quantities of 42 
fermented milk, rich in lactobacilli. Metchnikoff suggested that pathogens present in 43 
the intestine released toxins which were poisonous to the body and the consumption 44 
of fermented milk helped alleviate the effects of these pathogens and their toxins 45 
(Fuller, 1991, Vasiljevic and Shah, 2008, Dixon, 2002). The Food and Agriculture 46 
Organisation of the United Nations, and World Health Organisation jointly describe 47 
probiotics as live microorganisms that when administered in adequate amounts 48 
confer a health benefit on the host (FAO/WHO, 2002).  49 
For an organism to be considered as a probiotic, it must have been documented to 50 
have a health benefit (Sanders, 2009). Several health claims have been attributed to 51 
probiotics, some of these health claims are towards gastrointestinal health whereas 52 
others are intended for systemic benefits contributing towards overall general 53 
wellbeing. Gastrointestinal health claims attributed to probiotics include the 54 
alleviation of lactose intolerance, prevention of antibiotic-associated diarrhoea, and 55 
management of inflammatory bowel disease (Tung et al., 2009, Vasiljevic and Shah, 56 
2008, Gismondo et al., 1999, Guslandi et al., 2003, Mimura et al., 2004). Probiotics 57 
have also been reported to have roles in immune stimulation and modulation as well 58 
as in the management of obesity (Morita et al., 2002, Kato et al., 1999). Some 59 
probiotics have been reported to have anti-carcinogenic and cholesterol-lowering 60 
properties (Couteau et al., 2001, Tabuchi et al., 2003).  61 
The recent increased interest in probiotics also stems from the greater awareness of 62 
the human microbiome and its potential applications. An increased realisation of the 63 
need for alternatives to antibiotics has partly contributed to this. Even though 64 
antibiotics have been around for over 50 years, hospital infection rates are not 65 
declining and multi-drug resistant bacteria continue to emerge creating a major 66 
public health problem as a result  (Broeckx et al., 2016, Teughels et al., 2011). 67 
 4 
Ideally, a probiotic must have viable organisms at the point of consumption, 68 
minimum numbers of 106, 107, and 108 CFU/g at the point of consumption have been 69 
reported (Shah, 2007, Douglas and Sanders, 2008, Krishnakumar and Gordon, 70 
2001). The FAO/WHO, however, recommends that minimum viable numbers of each 71 
probiotic strain in a product at the end of the product’s shelf-life should be indicated 72 
on the product label. Probiotic formulations, upon consumption, must withstand 73 
gastrointestinal transit and colonise the intestines for benefits to be observed 74 
(FAO/WHO, 2002, Vasiljevic and Shah, 2008, Sanders, 2009). Dairy products 75 
supplemented with probiotics are a natural means of probiotics administration, 76 
however, for the purposes of prevention or treatment of diseases, specifically 77 
targeted applications, formulations, devices, or carriers with a slow release of 78 
probiotics might be needed (Meurman and Stamatova, 2007). There have been 79 
reports of commercial products exhibiting significant drops in viability after exposure 80 
to gastric fluids; other products have been reported with probiotic populations that do 81 
not correspond to numbers indicated on products (Hoa, 2000, Hamilton-Miller et al., 82 
2007, Fredua-Agyeman and Gaisford, 2015, Temmerman et al., 2003, Huff, 2004, de 83 
Vos et al., 2010, Masco et al., 2005, Charteris et al., 1998, Caillard and Lapointe, 84 
2017). 85 
Formulating probiotics can be challenging since product viability must be maintained 86 
during formulation and after consumption by consumers. Formulating products that 87 
can withstand the harshness of the gastrointestinal tract and target them to the 88 
intestines is currently receiving great interest as are formulation processes that are 89 
not deleterious to organisms (Kailasapthy, 2002, Mortazavian et al., 2007).  The aim 90 
of this work was, therefore, to assess the viability of some commercial probiotics 91 
after exposure to gastric acid and the possibility of modifying these formulations. The 92 
modification approach used here was the Phloral® coating technology to target 93 
probiotics to the colon. Phloral® consists of a blend of bacteria-activated (resistant 94 
starch) and pH-activated (Eudragit® S) components. The independent triggers of a 95 
bacterially-triggered component within a pH-responsive polymer are effective, 96 
complementary, and act as failsafe mechanisms for each other in drug delivery 97 
(Ibekwe et al., 2008, McConnell et al., 2008, D'Haens et al., 2017).  An assessment 98 
of the potential of these products to adhere to intestinal cells was also conducted.   99 
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2 Materials and methods 100 
2.1 Materials 101 
Pepsin, trehalose, xylitol, sucrose, and triton X-100 were purchased from Sigma, UK. 102 
Dulbecco’s Modified Eagle Medium, heat-inactivated foetal bovine serum, 103 
phosphate-buffered saline (PBS), 1% non-essential amino acid, and trypsin-ethylene 104 
diamine tetraacetic acid were from Gibco, UK.  de Man, Rogosa and Sharpe (MRS) 105 
agar and broth were from Oxoid, UK. Hydrochloric acid was purchased from VWR, 106 
UK. Sodium chloride was purchased from Fisher Scientific, UK. 107 
Three commercial probiotic products were bought from a health food shop and 108 
analysed. The choice of probiotics was limited to products that contain only 109 
lactobacilli strains; these are represented here as Products A, B, and C and their 110 
composition is indicated in Table 1. These probiotics were selected because they 111 
contain strains common to most probiotic products, and so the results have wide 112 
applicability. An in-house probiotic was also prepared by freeze-drying Lactobacillus 113 
acidophilus LA 5. 114 
Table 1: Composition of probiotic products used  115 
Product Formulation Composition Stated minimum 
content per 
capsule (x 108 
CFU) 
Product A  
 
Encapsulated 
dried powder  
Lactobacillus 
acidophilus PXN 35  
Lactobacillus 
plantarum PXN 47 
5 
Product B 
 
Encapsulated 
dried powder 
Lactobacillus 
plantarum LP 299v 
200 
Product C  
 
Encapsulated 
dried powder 
Lactobacillus 
plantarum CECT 
7527 
Lactobacillus 
plantarum CECT 
7528 
Lactobacillus 
plantarum CECT 
12 
 6 
7529 
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2.2 Preparation of freeze-dried probiotic 117 
An in-house freeze-dried probiotic formulation was prepared for comparison with the 118 
commercial products. Lactobacillus acidophilus LA5 was used as the model probiotic 119 
strain with 10% sucrose or 10% trehalose used as protectants.  120 
2.2.1 Cultivation of microorganism and preparation of bacterial culture  121 
Lactobacillus acidophilus was initially grown on MRS (de Man, Rogosa, and Sharpe) 122 
agar and incubated under anaerobic conditions for 48 hours at 37 ºC. A few colonies 123 
were taken and used to inoculate 7 mL of MRS broth to create a starter culture and 124 
incubated for 24 hours. 99 mL of fresh MRS broth was inoculated with 1 mL of 125 
starter culture to create a 1: 100 dilution and this was incubated for 24 hours. The 126 
culture was then mixed using a magnetic stirrer and 30 mL each was dispensed into 127 
3 falcon tubes (Tubes A, B, and C). Centrifugation was done at 9500 rpm and 4 ºC 128 
for 10 minutes to harvest the cells after which supernatant was removed carefully by 129 
suction. The cells were washed with PBS and centrifuged at 9500 rpm and 4 ºC for 130 
10 minutes. The supernatant was removed by suction and the washing process 131 
repeated. The cells in tube A were resuspended in ¼ Ringer’s solution only and 132 
tubes B and C resuspended in 10% sucrose and 10% trehalose in ¼ Ringer’s 133 
solution respectively. The bacterial cultures were mixed continuously using a 134 
magnetic stirrer and 2 mL aliquoted into sterile 5 mL glass vials for freeze-drying.  135 
2.2.2 Freeze-drying 136 
Freeze-drying was done with VirTis-Advantage freeze-dryer (UK). The samples were 137 
initially submerged under dry ice for about 60 minutes. Once frozen, the vials were 138 
transferred onto pre-cooled shelves in the freeze-dryer. The freezing and condenser 139 
temperatures were -40 oC and -60 oC respectively. The primary drying step was at -140 
20 oC for 48 hours. The vacuum pressure was maintained below 200 mBar.  141 
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Secondary drying was done at 20 oC for 3 hrs. Enumeration after freeze-drying was 142 
conducted and percentage recovery obtained. 143 
2.3 Evaluating viability of probiotic products  144 
The contents of one capsule of each commercial probiotic were suspended in 5 mL 145 
of PBS and vortexed for about 10 seconds and allowed to stand for 10 minutes and 146 
vortexed once more for homogeneity. These were then serially diluted and plated 147 
onto MRS agar. The agar plates were incubated at 37 oC under anaerobic conditions 148 
for 48 hours after which colonies were counted. 100 mg was used for the prepared 149 
freeze-dried formulation. 150 
 151 
2.4 Evaluating the in vitro adhesion of probiotics to intestinal cells 152 
The evaluation done here was similar to work carried out by Forestier et al. (2001).  153 
The growth medium used was Dulbecco’s Modified Eagle Medium supplemented 154 
with 10% of heat-inactivated foetal bovine serum and 1% non-essential amino acid. 155 
The prepared medium was used to routinely grow Caco-2 cells in cell culture flasks 156 
with surface area 75cm2 or to seed cells in a well-plate. All cells were incubated at 157 
37 oC in a humidified atmosphere of 5% CO2.  158 
Caco–2 monolayers were seeded at a concentration of 2 x 105 cells per well in 12-159 
well plates and incubated at 37 oC with humidified atmosphere of 5% CO2. Caco–2 160 
cells were used in the late post-confluence stage with passage numbers between 39 161 
and 54. Prior to adhesion testing, Caco–2 monolayers were washed twice with 1 mL 162 
PBS; 1 mL of the cell culture growth medium was then added to each well. The 163 
contents of one capsule of each commercial probiotic and 100 mg of the freeze-dried 164 
L. acidophilus strain were suspended in 5 mL of PBS. These were serially diluted 165 
such that the estimated bacterial numbers did not exceed the Caco-2 cell numbers. 166 
1mL of each test sample was then added to 1mL of growth medium in each well and 167 
plates incubated for an hour.  The monolayers were then washed three times with 1 168 
mL PBS to remove any non-adhered bacterial cells. The cells were lysed by addition 169 
of 1 mL 0.1% triton X-100 solution and the number of viable adhering bacteria 170 
determined by plating out serial dilutions onto MRS agar. The number of adhered 171 
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cells was then expressed as a percentage of the initial number. An estimate of the 172 
number of Caco–2 cells in the wells was made each time adhesion tests were 173 
performed. This was to ensure the available Caco-2 cells were not less in number 174 
than the bacterial cells being added. The Caco-2 cells used for these tests were 175 
between 2.9 x 105 – 1 x 106 cells per well.  176 
2.5 Evaluating tolerance to gastric fluids 177 
2.5.1 Preparation of Simulated Gastric fluid (SGF)  178 
100 mL of sodium chloride and hydrochloric acid (HCl) mixture was first prepared by 179 
dissolving 0.2 g of sodium chloride in 90 mL purified water. The pH was adjusted to 180 
1.2 with HCl and volume made up to 100 mL. 0.32 g of pepsin was then added to 50 181 
ml of the sodium chloride and HCl solution and stirred until complete dissolution. The 182 
volume was adjusted to 100 mL afterwards. The solution was filter-sterilised and 183 
used within 48 hours of preparation. 184 
2.5.2 Tolerance testing 185 
The contents of one capsule of each product were deposited into the SGF for 2 186 
hours. All the media were pre-warmed to 37 oC prior to use and bacterial 187 
enumeration was conducted at set times. To ensure the process was carried out at 188 
37 oC with 50 rpm paddle movement as observed in USP dissolution testing, a hot 189 
plate magnetic stirrer was used with temperature and speed set to 37 oC and 50 rpm 190 
respectively. 50 mL of gastric media in sterile duran bottles were used. Aliquots were 191 
taken at set times and enumeration of probiotic species conducted using MRS agar 192 
plates. The plates were incubated for 48 hours afterwards under anaerobic 193 
conditions. 100 mg was used for the prepared freeze-dried formulation.  194 
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2.6 Encapsulation of probiotics for site-specific delivery 195 
Capsules were coated using Phloral® – a coating technology developed at University 196 
College London that targets the release of drugs to the colon. The contents of one 197 
capsule of each commercial probiotic and 100 mg of the in-house freeze-dried L. 198 
acidophilus were then transferred into empty size 0 capsules (Qualicaps® USA) and 199 
coated using the Phloral® coating technology as reported by Ibekwe et al. (2008). 200 
These were then analysed using a modified dissolution testing method mimicking 201 
standard USP dissolution testing.  202 
Capsules were immersed in three consecutive media i.e., 0.1M HCl (2 hours), 203 
phosphate buffer at pH 6.8 (2 hours), and phosphate buffer at pH 7.4 (1 hour). All the 204 
media were pre-warmed to 37 oC prior to use. Bacterial enumeration was conducted 205 
at hourly intervals in all media. To ensure the process was carried out at 37 oC with 206 
50 rpm paddle movement as observed in USP dissolution testing; a hot plate 207 
magnetic stirrer was used with temperature and speed set to 37 oC and 50 rpm 208 
respectively. 50 mL media in sterile duran bottles were used and all capsules were 209 
completely immersed with the aid of sinkers.  210 
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3 Results and Discussion 211 
3.1 Freeze-drying Lactobacillus acidophilus LA5 212 
The freeze-dried formulations with the protectants yielded recoveries over 90%; a 213 
complete loss of viability was observed when no protectant was added (Table 2). 214 
 215 
Table 2: Percentage recovery after freeze-drying L. acidophilus LA5 using sugars as protectants 216 
Sample Percentage Recovery (%) 
Control 0 
10% Sucrose 92.94 ± 1.08 
10% Trehalose 94.22 ± 2.67 
 217 
Freeze-drying is a procedure based on sublimation under high vacuum, this occurs 218 
in three phases, i.e., freezing, primary drying, and secondary drying. During freeze-219 
drying, the formation of intracellular ice crystals and macromolecule denaturation 220 
results in the loss of viability; hence, to preserve cell viability, protectants are added 221 
(Santivarangkna et al., 2007, Zayed and Roos, 2004, De Giulio et al., 2005). There 222 
are numerous protectants used to improve cell viability during such procedures. 223 
Sugars have been reported to be beneficial to most lactobacilli during drying and 224 
upon storage; 10% sugar concentrations have been used with high recoveries after 225 
freeze-drying (Costa et al., 2000, Zhao and Zhang, 2005). In this study, 10% 226 
trehalose or 10% sucrose was, therefore, used as protectants during freeze-drying. 227 
Other additives like non-skimmed fat milk, polyols, polymers, amino acids have also 228 
been used (Efiuvwevwere et al., 1999, Costa et al., 2000). There is no single additive 229 
that fits all organisms, therefore, as best practice, a variety of excipients are explored 230 
during freeze-drying and the best excipient with the most improved viability chosen. 231 
Viabilities of 93% and 94% were obtained when 10% sucrose and 10% trehalose 232 
were used respectively as compared to a complete loss of viability when no 233 
protectant was included in freeze-drying L. acidophilus. De Giulio et al. (2005) also 234 
observed viabilities over 90% after freeze-drying some lactobacilli; they, however, 235 
used 32% sucrose and trehalose. The concentration of sugar used in freeze drying is 236 
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important; when Zayed and Roos (2004) used 4% sucrose and 4% trehalose as 237 
protectants, they could recover only 13% and 34% viabilities respectively after 238 
freeze-drying. They needed a combination of both amounts in addition to 18% 239 
skimmed milk to obtain 83-85% survival rates. 240 
 241 
3.2 Evaluating viability of product content  242 
An evaluation of the content in each of the products analysed is shown in Figure 1. 243 
All the products met the minimum indicated content on their packages, with Product 244 
A having more than 10 times the microorganisms as stated on product package.  245 
 246 
 247 
Figure 1: Bar chart illustrating the comparison between the expected and actual bacterial numbers per 248 
dose – a capsule each for the solid dose probiotics and 100 mg for freeze-dried (FD) strain – obtained 249 
after enumeration. 250 
 251 
With several studies as indicated in the introduction reporting about the lack of viable 252 
organisms or reduced numbers than what has been indicated on product packages, 253 
this was a good indication as it confirmed the probiotics had been well preserved and 254 
from the consumer’s point of view, gives confidence that the formulations purchased 255 
actually contain the stated number of bacteria. The presence of viable organisms 256 
after product formulation is key to ensuring probiotic activity.  257 
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3.3 In vitro adhesion of commercial probiotics to intestinal cells 258 
An enumeration of probiotic cells that adhered to intestinal cells for the products A, B 259 
and the freeze-dried strain showed that over 70% of the administered probiotics 260 
adhered to intestinal cells (Figure 2). Product C, however, had 64% of the 261 
administered probiotics adhering. 262 
 263 
Figure 2: An illustration of the percentage of administered probiotics that adhered to intestinal cells 264 
 265 
For probiotics delivered into the gastrointestinal tract to act, these need to colonise 266 
the intestines. Evaluation of probiotic colonisation in vivo is very challenging; a few 267 
studies have used the presence of probiotics in faeces as an indication of 268 
colonisation; this is, however, very speculative as faecal enumeration generally 269 
represents unadhered strains (Saxelin et al., 1993, Saxelin et al., 1995). An in vitro 270 
evaluation was demonstrated here whereby adhesion to Caco-2 intestinal cells was 271 
used to evaluate probiotic adhesion. This method of evaluation that ascertains 272 
probiotic organisms that adhere to intestinal cell lines as an in vitro model for has 273 
been reported (Govender et al., 2014, Maragkoudakis et al., 2006, Forestier et al., 274 
2001, Gopal et al., 2001, Tuomola and Salminen, 1998). More than half the number 275 
of the probiotic organisms administered adhered to intestinal cells, Products C which 276 
exhibited the least adhesion of the products tested had 64% of administered 277 
organisms adhering to Caco-2 cells. This indicated that all the dried probiotics 278 
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evaluated had the ability to adhere to intestinal cells and could possibly colonise the 279 
intestines should these arrive there.  280 
3.4 Evaluating tolerance to gastric fluids 281 
When the probiotics were exposed to simulated gastric fluid as shown in Figure 3, 282 
there was a sharp drop in viability within 5 minutes for all the solid dose probiotics 283 
evaluated; this reduction was circ. over 6 Log CFU.  284 
 285 
 286 
 287 
Figure 3: An illustration of probiotic population with time after exposure to fasted state simulated 288 
gastric fluid for products A-C and freeze-dried strain, FD. 289 
 290 
Gastric fluid is one of the barriers most biological preparations need to overcome to 291 
exert their impact. Even though some reports have highlighted the harshness of this 292 
medium to probiotics, others are of the perception that probiotics are acid-producing 293 
organisms and can, therefore, withstand the acidity of the stomach (Govender et al., 294 
2014, Sahadeva et al., 2011, Picot and Lacroix, 2004). Probiotics produce lactic 295 
acid, which is a weak acid and well tolerated by most probiotics as compared to 296 
gastric acid which is, 0.1 M HCl, a strong acid. In a study conducted to evaluate 297 
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some probiotic strains to gastric acid, only 1 of 15 probiotic strains was considered to 298 
be intrinsically resistant to gastric acid, the remaining strains were all killed (Charteris 299 
et al., 1998).  300 
When the probiotics were exposed to SGF, there was a significant drop in viability. It 301 
was observed that all the solid probiotics were just dried probiotics with no protective 302 
mechanisms against the gastric fluid. Such formulations have a low probability of 303 
delivering viable organisms into the intestines when taken. Fredua-Agyeman and 304 
Gaisford (2015) observed similar results when they evaluated the gastric acid 305 
tolerance of some commercial solid dose formulations. It is important for probiotics to 306 
be formulated with protective mechanisms against gastric fluid otherwise most 307 
probiotic strains could be killed during transit. The outcome of this test was worrying 308 
because 2 of the products, B and C, had inscriptions on their packages indicating the 309 
tolerance of the contained probiotic strains to gastric acid, the results here, however, 310 
demonstrated otherwise.  311 
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3.5 Encapsulation of probiotics for site-specific delivery 312 
When the probiotics were encapsulated using the Phloral® coating technology, no 313 
viable bacterial enumeration was obtained until after pH 7 when the threshold of 314 
dissolution for the coating material was reached. Bacterial enumeration at the target 315 
site was over 90% for all products, except for Product A which had a percentage 316 
recovery of 88% (Figure 4). 317 
 318 
 319 
Figure 4: An illustration of percentage recovery after Phloral® coated capsules (Products A – C and the 320 
freeze-dried strain, FD) were immersed consecutively in 0.1 M HCl and pH 6.8 for 2 hours then in pH 321 
7.4. 322 
 323 
With the distal parts of the gut as target sites, Phloral® coating technology was used. 324 
The main components of Phloral® are  Eudragit® S, which is a synthetic polymer that 325 
dissolves at pH > 7, and resistant starch, which is not digested by mammalian 326 
amylase enzymes secreted by the pancreas but by colonic bacterial enzymes; this 327 
makes the technology useful in drug targeting (Ibekwe et al., 2008, McConnell et al., 328 
2008, D'Haens et al., 2017). Upon capsule dissolution, it was observed that the 329 
probiotics investigated all had high viabilities with the lowest recorded viability being 330 
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88%. This confirms the need for most dried probiotics to be incorporated into gastro-331 
resistant formulations and delivered to the distal parts of the intestines. Some 332 
formulations have been reported whereby probiotics have been microencapsulated, 333 
although the reported recoveries have been low (Poelvoorde et al., 2008, Sultana et 334 
al., 2000). These formulations usually involve applying coating material directly to 335 
probiotics strains. The reduced viabilities could be because these coating materials 336 
themselves could have impacted directly on the organisms since organic solvents 337 
are sometimes used as ingredients in capsule coating (Cole et al., 2002, 338 
Huyghebaert et al., 2004). Optimisation of coating conditions may be needed to 339 
enhance product viability of these microencapsulated formulations. The need to 340 
protect probiotics was emphasised recently by Caillard and Lapointe (2017) when 341 
they evaluated some commercial probiotics and found that only the enteric-coated 342 
formulations had resistance after exposure to gastric acid at fasting and all the 343 
unprotected formulations had high drops in numbers after exposure. 344 
	  345 
  346 
  347 
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4 Conclusion 348 
The commercial products and freeze-dried L. acidophilus LA5 evaluated here all 349 
demonstrated poor tolerance to simulated gastric fluid even though some of these 350 
commercial products had inscriptions on product packs indicating tolerance of the 351 
contained probiotic strains to gastric acid. When the commercial and in- house 352 
freeze-dried probiotics were encapsulated using the Phloral® to target the delivery 353 
into lower small intestines or colon, viabilities of approximately 90% were observed 354 
after these capsules had been initially deposited in gastric acid for 2 hours. These 355 
products also demonstrated over 60% adhesion to intestinal cells in vitro highlighting 356 
the potential for colonisation should these overcome the harshness of the stomach. 357 
The need to target the delivery of probiotics into the intestines has been 358 
demonstrated here as this offers a greater potential for colonisation of the intestines 359 
once the harshness of the stomach has been overcome. 360 
 361 
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